Yttrium-90

DRUG4 trials

Sponsors

University of Minnesota, University of Michigan Rogel Cancer Center, Beth Israel Deaconess Medical Center, Li Qiang

Conditions

Bile Duct CancerCholangiocarcinomaCholangiocarcinoma MetastaticCholangiocarcinoma Non-resectableHepatocellular CarcinomaHepatocellular Carcinoma (HCC)Liver MalignancyMetastatic Intrahepatic Cholangiocarcinoma

Phase 1

Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.

RecruitingNCT04518748

University of Michigan Rogel Cancer CenterLiver Malignancy

Start: 2020-09-16End: 2028-11-30Target: 70Updated: 2025-08-05

Phase 2

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

RecruitingNCT05655949

Beth Israel Deaconess Medical CenterBile Duct Cancer, Cholangiocarcinoma, Cholangiocarcinoma Metastatic +2

Start: 2024-02-13End: 2027-12-01Target: 30Updated: 2025-03-10

Unknown Phase

Radioembolization of Primary and Secondary Liver Malignancies and The Effect On The Immune System

TerminatedNCT03889093

University of MinnesotaHepatocellular Carcinoma, Secondary Malignant Neoplasm of Liver

Start: 2018-08-09End: 2022-02-24Updated: 2025-03-24

A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Therapy) Therapy and Hepatic Arterial Infusion Chemotherapy (Hepatic Artery Infusion Chemotherapy) for Potentially Resectable Intermediate and Advanced Hepatocellular Carcinoma

RecruitingNCT07070076

Li QiangHepatocellular Carcinoma (HCC)

Start: 2026-08-01End: 2031-08-01Target: 286Updated: 2025-08-27

Related Papers

Sequential <sup>90</sup>Y Selective Internal Radiation Therapy (SIRT) and Stereotactic Body Radiation Therapy (SBRT) using <sup>90</sup>Y PET-based Absorbed Dose Maps: Interim Analysis of a Phase 1 Study.

2025-02-222 citations